Table 3.
Therapeutic cancer vaccine antigens from the NCI 2009 workshop as candidates for prophylactic vaccines: expression in precancer.
| NCI Ranka | Antigen | Oncogenica | Cancer stem cell expressiona | Premalignant lesion(s)b,c | Cancer typec |
|---|---|---|---|---|---|
| 1 | WT1 | yes | yes | nephrogenic rests | Kidney |
| 2 | MUC1 | yes | yes | PanIN, IPMN; BE; adenoma;bronchial preneoplasia; MGUS; AMM | pancreatic, esophageal,colorectal, lung, multiple myeloma |
| 3 | LMP2 | - | yes | ND | - |
| 4 | HPV E6 E7 | - | some | CIN, VIN | cervical |
| 5 | EGFRvIII | - | yes | ND | - |
| 6 | HER-2/neu | yes | - | DCIS; adenoma | breast, colorectal |
| 8 | MAGE A3 | - | yes | DCIS; SD; esophageal SCCIS | breast, head and neck, esophageal |
| 9 | p53 non- mutant | yes | yes | OL, OSMF; CIN; hyperplasia and dysplasia; schistosomal cystitis; SDIS; DH; dysplasia; DCIS | oral, cervical, head and neck, bladder, lung, pancreatic, breast |
| 10 | NY-ESO-1 | - | yes | DCIS; SD; SCIS | breast, head and neck, esophageal |
| 11 | PSMA | - | - | HGPIN | prostate |
| 13 | CEA | - | - | dysplasia, CIS; adenoma; IM | cervical, colorectal, gastric |
| 14 | MelanA/MART1 | - | - | BD, AK | melanoma |
| 15 | Ras-mutant | yes | yes | adenoma; EIN; BE; DH and dysplasia | colorectal, endometrial, esophageal, pancreatic |
| 17 | p53 mutant | yes | some | OL, OSMF; CIN; hyperplasia and dysplasia; schistosomal cystitis; SDIS; DH, dysplasia; DCIS; BE; AK, BD | oral, cervical, head and neck, bladder, lung, pancreatic, breast, esophageal, melanoma |
| 19 | Bcr-abl | yes | yes | ND | - |
| 20 | Tyrosinase | - | - | MIS, SSM | melanoma |
| 21 | Survivin | yes | - | OL; RIN; IPMT; BD | oral, renal, pancreatic, melanoma |
| 23 | hTERT | yes | yes | PanIN, IPMN; BD, AK | pancreatic, melanoma |
| 24 | Sarcoma translocation breakpoints | yes | yes | ND | - |
| 25 | EphA2 | yes | - | AAH, noninvasive bronchioloalveolar component of adenocarcinoma | lung |
| 27 | ML-IAP | yes | - | ND | - |
| 28 | AFP | - | yes | ND | - |
| 29 | EpCAM | - | yes | IM; IN | gastric and esophageal |
| 30 | ERG (TMPRSS2 ETS fusion gene) | yes | - | HGPIN | prostate |
| 32 | PAX3 | yes | - | neurofibroma | nerve sheath, melanoma |
| 33 | ALK | yes | yes | ND | - |
| 34 | Androgen receptor | yes | - | OL, OSMF; BPH, PIN | oral, prostate |
| 35 | Cyclin B1 | yes | - | bronchial preneoplasia; SD; DCIS | lung, head and neck, breast |
| 36 | Polysialic Acid | - | - | CIN; OL, OSMF | cervical, oral |
| 37 | MYCN | yes | - | ND | - |
| 38 | RhoC | yes | - | ND | - |
| 39 | TRP-2 | - | yes | ND | - |
| 42 | Mesothelin | - | - | PanIN, IPMN | pancreatic |
| 43 | PSCA | - | - | HGPIN | prostate |
| 44 | MAGE A1 | - | yes | DCIS; SD; SCCIS | breast, head and neck, esophageal |
| 45 | sLe(a) | - | - | adenoma; CIN | colorectal, cervical |
| 46 | CYP1B1 | - | - | PIN | prostate |
| 47 | PLAC1 | yes | - | DCIS | breast |
| 49 | BORIS | yes | - | ND | - |
| 50 | Tn | - | - | AK, BD; Paget's disease | melanoma, breast |
| 52 | ETV6-AML | yes | - | ND | - |
| 55 | SART3 | - | - | CIS | gastric |
| 56 | STn | - | - | adenoma, Crohn's colitis; IM | colorectal, gastric |
| 57 | Carbonic anhydrase IX | - | - | columnar cell metaplasia; BE, dysplasia | colorectal, esophageal |
| 58 | PAX5 | yes | - | ND | - |
| 59 | OY-TES1 | yes | - | ND | - |
| 66 | B7H3 | - | - | PIN | prostate |
a
Rankings from 2009 NCI Workshop reported in Cheever et al. 2009.
b
Premalignant lesions with validated expression on human tissue samples.
c
Listed cancer types correspond in order to listed premalignant lesions. Premalignant lesions of the same cancer tissue type are separated by commas while lesions of different tissue types are separated by semi-colons.